Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$462.88 USD

462.88
706,669

-0.27 (-0.06%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $462.85 -0.03 (-0.01%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Stock Reports for NIKE, Amgen & Morgan Stanley

Today's Research Daily features new research reports on 12 major stocks, including NIKE (NKE), Amgen (AMGN), and Morgan Stanley (MS).

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why

CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.25%: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $225.55, marking a -0.25% move from the previous day.

Ekta Bagri headshot

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $237 in the latest trading session, marking a +1.76% move from the prior day.

Kinjel Shah headshot

CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update

Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.

Kinjel Shah headshot

3 Biotech Technological Developments to Watch Out For in 2021

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study

Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.

Kinjel Shah headshot

5 Disruptive Biotech Stocks With Solid Long-Term Potential

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis

Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $234.46 in the latest trading session, marking a -0.59% move from the prior day.

Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More

Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.

Vertex (VRTX) Inks Deal with Skyhawk for Serious Diseases

Vertex (VRTX) signs a licensing agreement with privately held company Skyhawk Therapeutics to discover novel small molecules that modulate RNA splicing for treating serious diseases.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.08%: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $236.72 in the latest trading session, marking a -0.08% move from the prior day.

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $224.17, moving +0.06% from the previous trading session.

Kevin Cook headshot

CRISPR Gene Editing: Owning the Future of Medicine

In the Century of Biology, it pays to own the future of curing disease at the root.

Editas (EDIT) Submits Application to Start Study on EDIT-301

Editas (EDIT) files an IND application to the FDA for beginning a phase I/II study of EDIT-301 to treat SCD.

Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News

Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.

CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows sustained response to treatment in patients with transfusion-dependent beta thalassemia as well as sickle cell disease. Shares rise.

Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More

Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.

Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod

Vertex (VRTX) gets European approval for label expansion of Symkevi and Kalydeco combination pill in cystic fibrosis patients aged six to 11.